BackRelmada Therapeutics Overview

Relmada Therapeutics Long Term Debt

Track Relmada Therapeutics's long-term debt ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer trimmed avg / median

Loading

Relmada Therapeutics Long Term Debt History

Loading

Relmada Therapeutics vs. peers: Long Term Debt Comparison

Loading

Relmada Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Relmada Therapeutics (RLMD) FAQ

As of the most recent data (June 2026), RLMD shows a long-term debt of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RLMD's long-term debt is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Relmada Therapeutics is outperforming or lagging.

Tracking RLMD's long-term debt over time shows whether Relmada Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Relmada Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $0) with ownership activity and broader fundamentals.

Relmada Therapeutics's long-term debt is $0; compare it with other Consumer Discretionary names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.